Reduced-dose dexamethasone premedication for weekly paclitaxel: a retrospective cohort study of early hypersensitivity reactions and steroid-related toxicity
Supportive Care in Cancer · 2026-07 · 34 (7)
DOI: 10.1007/s00520-026-10933-2 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Supportive Care in Cancer, online erschienen am 29.06.2026. Verfasst von Jeayoon Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-Ro, Gwanak-Gu, Seoul, 08826, Republic of K…. Hauptthemen laut MEDLINE: Dexamethasone, Paclitaxel, Drug Hypersensitivity, Antineoplastic Agents, Phytogenic. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University.
Abstract (Originalsprache)
Purpose
Taxane-induced hypersensitivity reactions (HSRs) are highly prevalent, necessitating premedication with dexamethasone; however, prolonged or high-dose exposure to dexamethasone increases the risk of adverse effects. This study evaluated whether a reduced-dose dexamethasone regimen effectively prevents HSRs while minimizing steroid-related toxicity during weekly paclitaxel chemotherapy.
Methods
This retrospective cohort study utilized electronic health records to evaluate patients receiving weekly paclitaxel. We compared a low-dose (LD) dexamethasone regimen (10 mg at the first infusion, followed by 4 mg weekly) with a conventional high-dose (HD) regimen (10 mg weekly). The primary outcome was the incidence of HSRs during the second paclitaxel infusion, analyzed using non-inferiority testing with a predefined margin of 2%. Propensity score-based inverse probability of treatment weighting was employed to control confounding, with missing data addressed via multiple imputation. Secondary outcomes included the incidence of steroid-related adverse events (AEs) such as hyperglycemia, insomnia, and serious bacterial infections, evaluated using Cox proportional hazards models adjusted for relevant clinical factors.
Results
The LD regimen was non-inferior to the HD regimen for preventing HSRs (weighted incidence, 0.72% vs. 1.18%; risk difference −0.46%; 95% CI −1.26% to 0.53%). The HD group had a significantly higher risk of hyperglycemia (adjusted HR [aHR] 1.54, 95% confidence interval [CI] 1.15 to 2.07). While insomnia (aHR 1.53, 95% CI 0.93 to 2.51) and serious bacterial infections (aHR 1.19, 95% CI 0.99 to 1.44) occurred more frequently in the HD group, these trends did not reach statistical significance.
Conclusion
A low-dose dexamethasone premedication regimen was non-inferior to the conventional regimen in preventing HSRs and was associated with a lower risk of corticosteroid-associated hyperglycemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-Ro, Gwanak-Gu, Seoul, 08826, Republic of Korea.
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-Ro, Gwanak-Gu, Seoul, 08826, Republic of Korea. moko@cu.ac.kr.
- College of Pharmacy, Daegu Catholic University, Gyeongsan-Si, 38430, Gyeongbuk, Republic of Korea. moko@cu.ac.kr.
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-Ro, Gwanak-Gu, Seoul, 08826, Republic of Korea. jmoh@snu.ac.kr.
- College of Pharmacy, Natural Products Research Institute, Seoul National University, Seoul, Republic of Korea. jmoh@snu.ac.kr.
Förderung
- Seoul National University
Zitieren
APA
Lee, J., An, Y., Kim, I. W., Ko, M., & Oh, J. M. (2026). Reduced-dose dexamethasone premedication for weekly paclitaxel: a retrospective cohort study of early hypersensitivity reactions and steroid-related toxicity. Supportive Care in Cancer, 34(7). https://doi.org/10.1007/s00520-026-10933-2
Vancouver
Lee J, An Y, Kim IW, Ko M, Oh JM. Reduced-dose dexamethasone premedication for weekly paclitaxel: a retrospective cohort study of early hypersensitivity reactions and steroid-related toxicity. Supportive Care in Cancer. 2026;34(7). doi:10.1007/s00520-026-10933-2
BibTeX
@article{Lee2026,
author = {Lee, Jeayoon and An, Yijin and Kim, In-Wha and Ko, Minoh and Oh, Jung Mi},
title = {Reduced-dose dexamethasone premedication for weekly paclitaxel: a retrospective cohort study of early hypersensitivity reactions and steroid-related toxicity},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {7},
doi = {10.1007/s00520-026-10933-2}
}
EUVIMED